Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies

HIV-1 gp41 Core with Exposed Membrane-Proximal External Region Inducing Broad HIV-1 Neutralizing Antibodies

The membrane-proximal external region (MPER) of the HIV-1 gp41 consists of epitopes for the broadly cross-neutralizing monoclonal antibodies 2F5 and 4E10. However, antigens containing the linear sequence of these epitopes are unable to elicit potent and broad neutralizing antibody responses in vaccinated hosts, possibly because of inappropriate conformation of these epitopes. Here we designed a...

Generation of HIV-1 potent and broad neutralizing antibodies by immunization with postfusion HR1/HR2 complex.

BACKGROUND The envelope glycoproteins are major targets for HIV vaccines. The N-terminal and the C-terminal regions of the gp41 interact to form six helix bundles that are responsible for the fusion between the viral and the target cell membranes. Monoclonal antibodies (Abs) able to disrupt the formation of this complex or to interfere with it could inhibit HIV fusion. Most of the well describe...

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals, define critical epitopes for HIV vaccine design. Using a systematic approach, we have examined neutralization breadth in the sera of about 1800 HIV-1-infected individuals, primarily infected with non-clade B viruses, and have selected donors for monoclonal antibody (mAb) generation. We then used...

Antibodies in 2F5 Knock-in Mice: Selection Induction of HIV-1 Broad Neutralizing

HIV vaccine development and broadly neutralizing antibodies

Human immunodeficiency virus-1 (HIV-1) infects about 35 million people worldwide [1]. There is no vaccine in current clinical use. Although available drug treatments are generally effective in controlling infection, they are not curative, can cause significant side effects and are unable to prevent comorbidities such as cardiovascular disease and cancers. In 2012, about 1.6 million people world...